No … prostate cancer cannot be transmitted, from men to men or from men to women but …
Filed under: Risk, Uncategorized | Tagged: PSA, Skene's glands, transmission, women | Leave a Comment »
Of PSA in women, prostate cancer transmission, and other important matters
Posted on May 6, 2009 by Sitemaster
What’s hot on the internet? Physician ratings web sites!
Posted on May 6, 2009 by Sitemaster
A recent article on Medscape is titled “Physician-ratings websites get zero stars from doctors,”
Filed under: Living with Prostate Cancer | Tagged: doctor-patient relationship | 2 Comments »
The Dana Jennings report …
Posted on May 5, 2009 by Sitemaster
… for the week can be found in the New York Times online under the heading “Cancer in Winter, Optimism in Spring.”
Filed under: Living with Prostate Cancer | Tagged: Dana Jennings | Comments Off
The clinical relevance of new biomarkers is tricky
Posted on May 5, 2009 by Sitemaster
Assiduous readers of this blog will have noted that there are relatively frequent mentions of “new” biomarkers that may have potential as indicators of the aggressiveness of prostate cancer — but that in most cases those biomarkers are never heard of again.
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Risk | Tagged: biomarkers | 1 Comment »
New prostate cancer trials web service
Posted on May 5, 2009 by Sitemaster
A company called Accrual Solutions has built the first phase of a new service that allows patients to search for prostate cancer-specific clinical trials.
Filed under: Drugs in development, Management, Treatment | Tagged: clinical trials | Leave a Comment »
The prostate cancer news report: Tuesday, May 5, 2009
Posted on May 5, 2009 by Sitemaster
We are returning to “normal” today with the standard “news reports.” Today’s items deal with: Evolving biomarkers and new tests and their future application MRI in diagnosis, staging, and prognosis of prostate cancer Intraprostatic injection of LHRH agonists and antagonists: is it viable? Gefitinib in HRPC: no evident impact on quality of life
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: agonist, antagonist, biomarkers, gefitinib, Iressa, LHRH, magnetic resonance imaging, MRI | 2 Comments »
New updates to this web site
Posted on May 4, 2009 by Sitemaster
Given the current news hiatus following the AUA meeting, we have been able to spend the last couple of days making modifications to the main web site content, with particular emphasis on the role of PSA testing and risk for prostate cancer.
Filed under: Uncategorized | Comments Off
Olmert to have prostate cancer surgery
Posted on May 3, 2009 by Sitemaster
After some 18 months on active surveillance, Israel’s former prime minister Ehud Olmert has decided to have prostate cancer surgery in the USA in very near future.
Filed under: Management, Treatment | Tagged: Olmert surgery | Leave a Comment »
The new AUA guidance on PSA testing: a critical analysis
Posted on May 2, 2009 by Sitemaster
So now that the stream of data from the American Urology Association annual meeting appears to have run its course, we thought this might be an opportune moment to look very carefully at the new “best practice statement” on PSA testing issued at the meeting, with a particular focus on the use of PSA testing [...]
Filed under: Diagnosis, Risk | Tagged: AUA, best practice statement, PSA, risk, testing | 7 Comments »
Phase III trial of intermittent degarelix therapy to be started
Posted on May 1, 2009 by Sitemaster
Ferring Pharmaceuticals has announced the company’s intent to initiate a randomized, controlled, multi-center trial of degarelix used as intermittent androgen deprivation therapy (IADT) in patients with advanced prostate cancer who have rising serum PSA levels after previous curative therapies.
Filed under: Drugs in development, Management, Treatment | Tagged: Degarelix, intermittent androgen deprivation therapy. IADT | Leave a Comment »
AUA report and update no. 12: Friday, May 1, 2009
Posted on May 1, 2009 by Sitemaster
And still the stream of information continues, with reports about frequency of PSA testing, nerve-sparing in men with Gleason 6 disease, and HIFU as a form of salvage therapy after first-line radiation:
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: frequency, HIFU, nerve-sparing, salvage, screening | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site
